Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11415211 | 1.00 | GSR (0.44) | GSRNOS1NOS3NOS2LTA4H | |
| SCHEMBL11415214 | 1.00 | GSR (0.44) | GSRNOS1NOS3NOS2LTA4H | |
| Hydrochloric Acid SCHEMBL11272393 | 0.98 | GSR (0.42) | GSRNOS1NOS3NOS2LTA4H | |
| SCHEMBL866977 | 0.94 | GSR (0.52) | GSRNOS1NOS3NOS2LTA4H | |
| SCHEMBL855342 | 0.94 | GSR (0.52) | GSRNOS1NOS3NOS2LTA4H | |
| SCHEMBL1309368 | 0.93 | GSR (0.50) | GSRNOS1LTA4HCPB2DPP7 | |
| Hydrochloric Acid SCHEMBL3088557 | 0.93 | GSR (0.50) | GSRNOS1NOS3NOS2LTA4H | |
| SCHEMBL1309450 | 0.93 | GSR (0.50) | GSRNOS1LTA4HCPB2DPP7 | |
| SCHEMBL1310240 | 0.93 | GSR (0.50) | GSRNOS1LTA4HCPB2DPP7 | |
| SCHEMBL2131918 | 0.93 | GSR (0.50) | GSRNOS1LTA4HCPB2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036671-A | Tetramethyl rhodamine-marked agmatine fluorescent probe and preparation method and application thereof | 中国人民解放军陆军特色医学中心 | 2026-05-15 | — | — | CN | claimed |
| CN-106632189-A | Preparation method of N alpha- fluorenylmethoxycarbonyl-N Epsilon-7-methoxycoumarin-4-acetyl-lysine/ornithine | 吉尔生化（上海）有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-122036671-A | Tetramethyl rhodamine-marked agmatine fluorescent probe and preparation method and application thereof | 中国人民解放军陆军特色医学中心 | 2026-05-15 | — | — | CN | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4663632-A1 | COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING | Sulis Therapeutics ApS (DK) | 2025-12-17 | — | — | EP | disclosed |
| EP-4551210-A1 | BIFACIAL PEPTIDE NUCLEIC ACID PROBES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025073956-A1 | STING ANTAGONIST COMPOUNDS | SULIS THERAPEUTICS APS (DK) | 2025-04-10 | — | — | WO | disclosed |
| EP-4534147-A1 | STING ANTAGONIST COMPOUNDS | Sulis Therapeutics ApS (DK) | 2025-04-09 | — | — | EP | disclosed |
| CN-119350422-B | Deubiquitinase targeting chimeric compound and preparation method and application thereof | 中国药科大学 | 2025-04-04 | — | — | CN | disclosed |
| EP-4527828-A1 | BIPHENYL COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | Longivitron (Suzhou) Biotechnology Co., Ltd (CN) | 2025-03-26 | — | — | EP | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| US-4658015-A | ANTAGONIST OF VASSOPRESSIN AND OXYTOCIN | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-14 | — | — | US | disclosed |
| US-4604378-A | CYCLIC POLYPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0182627-A2 | Basic V1-vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4543349-A | Basic heptapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-24 | — | — | US | disclosed |
| EP-0135379-A2 | Basic hexa- and hepta-peptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| US-RE30496-E | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1981-01-27 | — | — | US | disclosed |
| US-4207315-A | Process for treating proliferative skin diseases using certain diamino compounds | UNIVERSITY PATENTS, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| US-4201788-A | Process for alleviating proliferative skin diseases | UNIVERSITY PATENTS, INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4018912-A | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | GSR 4058/4885NOS1 64/4885NOS3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.